Pfizer gets new rebuff from NICE for cancer drug

LONDON (Reuters) - Pfizer suffered a second rejection in two days from health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.

The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.

The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.

In both cases, the NICE recommendations are preliminary and subject to further consultation.

(Reporting by Ben Hirschler; Editing by Mark Potter)

View the original article here

Pfizer lung cancer pill rejected by NICE

Mar 26 (Reuters) - Leading money winners on the 2013 PGATour on Monday (U.S. unless stated): 1. Tiger Woods $3,787,600 2. Brandt Snedeker $2,859,920 3. Matt Kuchar $2,154,500 4. Steve Stricker $1,820,000 5. Phil Mickelson $1,650,260 6. Hunter Mahan $1,553,965 7. John Merrick $1,343,514 8. Dustin Johnson $1,330,507 9. Russell Henley $1,313,280 10. Kevin Streelman $1,310,343 11. Keegan Bradley $1,274,593 12. Charles Howell III $1,256,373 13. Michael Thompson $1,254,669 14. Brian Gay $1,171,721 15. Justin Rose $1,155,550 16. Jason Day $1,115,565 17. Chris Kirk $1,097,053 18. ...

View the original article here